CompletedPhase 1NCT00982774

Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Access to Advanced Health Institute (AAHI)
Principal Investigator
Eltahir AG Khalil, MBBS
IEND
Intervention
LEISH-F2 + MPL-SE vaccine(biological)
Enrollment
42 target
Eligibility
7-40 years · All sexes
Timeline
20092011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00982774 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials